{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:13:36Z","timestamp":1790892816115,"version":"4.1.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:00:00Z","timestamp":1691971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:00:00Z","timestamp":1691971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Key Research and Development Projects","award":["2022YFC3602400, 2022YFC3602401"],"award-info":[{"award-number":["2022YFC3602400, 2022YFC3602401"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82271369"],"award-info":[{"award-number":["82271369"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Provincial Key Plan for Research and Development of Hunan","award":["2020SK2067"],"award-info":[{"award-number":["2020SK2067"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In addition to decreasing the level of cholesterol, proprotein convertase subtilis kexin 9 (PCSK9) inhibitor has pleiotropic effects, including immune regulation. However, the impact of PCSK9 on autoimmune diseases is controversial. Therefore, we used drug target Mendelian randomization (MR) analysis to investigate the effect of PCSK9 inhibitor on different autoimmune diseases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We collected single nucleotide polymorphisms (SNPs) of PCSK9 from published genome-wide association studies statistics and conducted drug target MR analysis to detect the causal relationship between PCSK9 inhibitor and the risk of autoimmune diseases. 3-Hydroxy-3-methylglutaryl-assisted enzyme A reductase (HMGCR) inhibitor, the drug target of statin, was used to compare the effect with that of PCSK9 inhibitor. With the risk of coronary heart disease as a positive control, primary outcomes included the risk of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), myasthenia gravis (MG), multiple sclerosis (MS), asthma, Crohn\u2019s disease (CD), ulcerative colitis (UC), and type 1 diabetes (T1D).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>PCSK9 inhibitor significantly reduced the risk of SLE (OR [95%CI]\u2009=\u20090.47 [0.30 to 0.76], <jats:italic>p<\/jats:italic>\u2009=\u20091.74\u2009\u00d7\u200910<jats:sup>\u22123<\/jats:sup>) but increased the risk of asthma (OR [95%CI]\u2009=\u20091.15 [1.03 to 1.29], <jats:italic>p<\/jats:italic>\u2009=\u20091.68\u2009\u00d7\u200910<jats:sup>\u22122<\/jats:sup>) and CD (OR [95%CI]\u2009=\u20091.38 [1.05 to 1.83], <jats:italic>p<\/jats:italic>\u2009=\u20092.28\u2009\u00d7\u200910<jats:sup>\u22122<\/jats:sup>). In contrast, HMGCR inhibitor increased the risk of RA (OR [95%CI]\u2009=\u20091.58 [1.19 to 2.11], <jats:italic>p<\/jats:italic>\u2009=\u20091.67\u2009\u00d7\u200910<jats:sup>\u22123<\/jats:sup>), asthma (OR [95%CI]\u2009=\u20091.21 [1.04 to 1.40], <jats:italic>p<\/jats:italic>\u2009=\u20091.17\u2009\u00d7\u200910<jats:sup>\u22122<\/jats:sup>), and CD (OR [95%CI]\u2009=\u20091.60 [1.08 to 2.39], <jats:italic>p<\/jats:italic>\u2009=\u20092.04\u2009\u00d7\u200910<jats:sup>\u22122<\/jats:sup>).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>PCSK9 inhibitor significantly reduced the risk of SLE but increased the risk of asthma and CD. In contrast, HMGCR inhibitor may be a risk factor for RA, asthma, and CD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-023-03122-7","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T09:02:11Z","timestamp":1692003731000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Causal relationship between PCSK9 inhibitor and autoimmune diseases: a drug target Mendelian randomization study"],"prefix":"10.1186","volume":"25","author":[{"given":"Weijia","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9154-131X","authenticated-orcid":false,"given":"Jian","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,14]]},"reference":[{"issue":"3\u20134","key":"3122_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jaut.2009.09.008","volume":"33","author":"GS Cooper","year":"2009","unstructured":"Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun. 2009;33(3\u20134):197\u2013207.","journal-title":"J Autoimmun"},{"issue":"10188","key":"3122_CR2","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/S0140-6736(19)30237-5","volume":"393","author":"L Durcan","year":"2019","unstructured":"Durcan L, O\u2019Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet (London, England). 2019;393(10188):2332\u201343.","journal-title":"Lancet (London, England)"},{"issue":"1","key":"3122_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cell.2020.03.007","volume":"181","author":"L Fugger","year":"2020","unstructured":"Fugger L, Jensen LT, Rossjohn J. Challenges, progress, and prospects of Developing therapies to treat autoimmune diseases. Cell. 2020;181(1):63\u201380.","journal-title":"Cell"},{"issue":"12","key":"3122_CR4","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1002\/acr.22091","volume":"65","author":"KP Liao","year":"2013","unstructured":"Liao KP, Cai T, Gainer VS, Cagan A, Murphy SN, Liu C, et al. Lipid and lipoprotein levels and trend in rheumatoid arthritis compared to the general population. Arthritis Care Res (Hoboken). 2013;65(12):2046\u201350.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"3122_CR5","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.3390\/nu14061240","volume":"14","author":"H VanEvery","year":"2022","unstructured":"VanEvery H, Yang W, Su J, Olsen N, Bao L, Lu B, et al. Low-density lipoprotein cholesterol and the risk of rheumatoid arthritis: a prospective study in a Chinese cohort. Nutrients. 2022;14(6):1240.","journal-title":"Nutrients"},{"key":"3122_CR6","doi-asserted-by":"publisher","first-page":"108637","DOI":"10.1016\/j.clim.2020.108637","volume":"222","author":"B Campos-Lopez","year":"2021","unstructured":"Campos-Lopez B, Meza-Meza MR, Parra-Rojas I, Ruiz-Ballesteros AI, Vizmanos-Lamotte B, Munoz-Valle JF, et al. Association of cardiometabolic risk status with clinical activity and damage in systemic lupus erythematosus patients: a cross-sectional study. Clin Immunol. 2021;222:108637.","journal-title":"Clin Immunol"},{"issue":"8","key":"3122_CR7","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/ki.2010.525","volume":"79","author":"HN Reich","year":"2011","unstructured":"Reich HN, Gladman DD, Urowitz MB, Bargman JM, Hladunewich MA, Lou W, et al. Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. Kidney Int. 2011;79(8):914\u201320.","journal-title":"Kidney Int"},{"issue":"2","key":"3122_CR8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1161\/01.STR.0000254476.05620.14","volume":"38","author":"J Mikdashi","year":"2007","unstructured":"Mikdashi J, Handwerger B, Langenberg P, Miller M, Kittner S. Baseline disease activity, hyperlipidemia, and hypertension are predictive factors for ischemic stroke and stroke severity in systemic lupus erythematosus. Stroke. 2007;38(2):281\u20135.","journal-title":"Stroke"},{"issue":"7","key":"3122_CR9","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jacc.2022.05.041","volume":"80","author":"DB Rosoff","year":"2022","unstructured":"Rosoff DB, Bell AS, Jung J, Wagner J, Mavromatis LA, Lohoff FW. Mendelian randomization study of PCSK9 and HMG-CoA reductase inhibition and cognitive function. J Am Coll Cardiol. 2022;80(7):653\u201362.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"3122_CR10","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1177\/0961203320926253","volume":"29","author":"A Liu","year":"2020","unstructured":"Liu A, Rahman M, Hafstrom I, Ajeganova S, Frostegard J. Proprotein convertase subtilisin kexin 9 is associated with disease activity and is implicated in immune activation in systemic lupus erythematosus. Lupus. 2020;29(8):825\u201335.","journal-title":"Lupus"},{"key":"3122_CR11","doi-asserted-by":"publisher","first-page":"1759720X2097590","DOI":"10.1177\/1759720X20975904","volume":"12","author":"H Sanchez-Perez","year":"2020","unstructured":"Sanchez-Perez H, Quevedo-Abeledo JC, Tejera-Segura B, de Armas-Rillo L, Rua-Figueroa I, Gonzalez-Gay MA, et al. Proprotein convertase subtilisin\/kexin type 9 is related to disease activity and damage in patients with systemic erythematosus lupus. Ther Adv Musculoskelet Dis. 2020;12:1759720X20975904.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"6","key":"3122_CR12","first-page":"1013","volume":"34","author":"I Ferraz-Amaro","year":"2016","unstructured":"Ferraz-Amaro I, Lopez-Mejias R, Ubilla B, Genre F, Tejera-Segura B, de Vera-Gonzalez AM, et al. Proprotein convertase subtilisin\/kexin type 9 in rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(6):1013\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"3122_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/1744666X.2022.2017281","volume":"18","author":"J Frostegard","year":"2022","unstructured":"Frostegard J. The role of PCSK9 in inflammation, immunity, and autoimmune diseases. Expert Rev Clin Immunol. 2022;18(1):67\u201374.","journal-title":"Expert Rev Clin Immunol"},{"key":"3122_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2017.04.023","volume":"262","author":"ZH Tang","year":"2017","unstructured":"Tang ZH, Peng J, Ren Z, Yang J, Li TT, Li TH, et al. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4\/NF-kappaB pathway. Atherosclerosis. 2017;262:113\u201322.","journal-title":"Atherosclerosis"},{"issue":"3","key":"3122_CR15","doi-asserted-by":"publisher","first-page":"e023328","DOI":"10.1161\/JAHA.121.023328","volume":"11","author":"E Punch","year":"2022","unstructured":"Punch E, Klein J, Diaba-Nuhoho P, Morawietz H, Garelnabi M. Effects of PCSK9 targeting: alleviating oxidation, inflammation, and atherosclerosis. J Am Heart Assoc. 2022;11(3):e023328.","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"3122_CR16","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1177\/0962280215597579","volume":"26","author":"S Burgess","year":"2017","unstructured":"Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for Mendelian randomization. Stat Methods Med Res. 2017;26(5):2333\u201355.","journal-title":"Stat Methods Med Res"},{"issue":"3","key":"3122_CR17","doi-asserted-by":"publisher","first-page":"e1003062","DOI":"10.1371\/journal.pmed.1003062","volume":"17","author":"TG Richardson","year":"2020","unstructured":"Richardson TG, Sanderson E, Palmer TM, Ala-Korpela M, Ference BA, Davey Smith G, et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. PLoS Med. 2020;17(3):e1003062.","journal-title":"PLoS Med"},{"issue":"11","key":"3122_CR18","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/ng.2797","volume":"45","author":"CJ Willer","year":"2013","unstructured":"Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45(11):1274\u201383.","journal-title":"Nat Genet"},{"issue":"10","key":"3122_CR19","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/ng.3396","volume":"47","author":"M Nikpay","year":"2015","unstructured":"Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet. 2015;47(10):1121\u201330.","journal-title":"Nat Genet"},{"issue":"12","key":"3122_CR20","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/ng.3434","volume":"47","author":"J Bentham","year":"2015","unstructured":"Bentham J, Morris DL, Graham DSC, Pinder CL, Tombleson P, Behrens TW, et al. Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. Nat Genet. 2015;47(12):1457\u201364.","journal-title":"Nat Genet"},{"issue":"5","key":"3122_CR21","doi-asserted-by":"publisher","first-page":"e2108672119","DOI":"10.1073\/pnas.2108672119","volume":"119","author":"R Chia","year":"2022","unstructured":"Chia R, Saez-Atienzar S, Murphy N, Chio A, Blauwendraat C, International Myasthenia Gravis Genomics C, et al. Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study. Proc Natl Acad Sci U S A. 2022;119(5):e2108672119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"3122_CR22","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1136\/annrheumdis-2020-219065","volume":"80","author":"E Ha","year":"2021","unstructured":"Ha E, Bae SC, Kim K. Large-scale meta-analysis across East Asian and European populations updated genetic architecture and variant-driven biology of rheumatoid arthritis, identifying 11 novel susceptibility loci. Ann Rheum Dis. 2021;80(5):558\u201365.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"3122_CR23","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/ng.2770","volume":"45","author":"AH Beecham","year":"2013","unstructured":"International Multiple Sclerosis Genetics C, Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013;45(11):1353\u201360.","journal-title":"Nat Genet"},{"issue":"1","key":"3122_CR24","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/s42003-021-02227-6","volume":"4","author":"K Valette","year":"2021","unstructured":"Valette K, Li Z, Bon-Baret V, Chignon A, B\u00e9rub\u00e9 JC, Eslami A, et al. Prioritization of candidate causal genes for asthma in susceptibility loci derived from UK Biobank. Commun Biol. 2021;4(1):700.","journal-title":"Commun Biol"},{"issue":"2","key":"3122_CR25","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/ng.3760","volume":"49","author":"KM de Lange","year":"2017","unstructured":"de Lange KM, Moutsianas L, Lee JC, Lamb CA, Luo Y, Kennedy NA, et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet. 2017;49(2):256\u201361.","journal-title":"Nat Genet"},{"issue":"9","key":"3122_CR26","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/ng.3359","volume":"47","author":"JZ Liu","year":"2015","unstructured":"Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015;47(9):979\u201386.","journal-title":"Nat Genet"},{"issue":"4","key":"3122_CR27","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/ng.3245","volume":"47","author":"S Onengut-Gumuscu","year":"2015","unstructured":"Onengut-Gumuscu S, Chen WM, Burren O, Cooper NJ, Quinlan AR, Mychaleckyj JC, et al. Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. Nat Genet. 2015;47(4):381\u20136.","journal-title":"Nat Genet"},{"issue":"12","key":"3122_CR28","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/art.42304","volume":"74","author":"XF Wang","year":"2022","unstructured":"Wang XF, Xu WJ, Wang FF, Leng R, Yang XK, Ling HZ, et al. Telomere length and development of systemic lupus erythematosus: a Mendelian randomization study. Arthritis Rheumatol (Hoboken, NJ). 2022;74(12):1984\u201390.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"3122_CR29","doi-asserted-by":"publisher","first-page":"e34408","DOI":"10.7554\/eLife.34408","volume":"7","author":"G Hemani","year":"2018","unstructured":"Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-base platform supports systematic causal inference across the human phenome. Elife. 2018;7:e34408.","journal-title":"Elife"},{"issue":"5","key":"3122_CR30","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","volume":"50","author":"M Verbanck","year":"2018","unstructured":"Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693\u20138.","journal-title":"Nat Genet"},{"issue":"1","key":"3122_CR31","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41467-020-14389-8","volume":"11","author":"N Papadimitriou","year":"2020","unstructured":"Papadimitriou N, Dimou N, Tsilidis KK, Banbury B, Martin RM, Lewis SJ, et al. Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis. Nat Commun. 2020;11(1):597.","journal-title":"Nat Commun"},{"issue":"7","key":"3122_CR32","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s11910-022-01197-4","volume":"22","author":"DG Hackam","year":"2022","unstructured":"Hackam DG, Hegele RA. Lipid-modifying therapies and stroke prevention. Curr Neurol Neurosci Rep. 2022;22(7):375\u201382.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"3122_CR33","doi-asserted-by":"publisher","first-page":"173114","DOI":"10.1016\/j.ejphar.2020.173114","volume":"878","author":"E Gallego-Colon","year":"2020","unstructured":"Gallego-Colon E, Daum A, Yosefy C. Statins and PCSK9 inhibitors: a new lipid-lowering therapy. Eur J Pharmacol. 2020;878:173114.","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"3122_CR34","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/cvr\/cvz313","volume":"116","author":"Z Ding","year":"2020","unstructured":"Ding Z, Pothineni NVK, Goel A, Luscher TF, Mehta JL. PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1. Cardiovasc Res. 2020;116(5):908\u201315.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"3122_CR35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.120.046290","volume":"143","author":"Z Qi","year":"2021","unstructured":"Qi Z, Hu L, Zhang J, Yang W, Liu X, Jia D, et al. PCSK9 (proprotein convertase subtilisin\/kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36. Circulation. 2021;143(1):45\u201361.","journal-title":"Circulation"},{"issue":"7839","key":"3122_CR36","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-020-2911-7","volume":"588","author":"X Liu","year":"2020","unstructured":"Liu X, Bao X, Hu M, Chang H, Jiao M, Cheng J, et al. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature. 2020;588(7839):693\u20138.","journal-title":"Nature"},{"issue":"6","key":"3122_CR37","doi-asserted-by":"publisher","first-page":"970","DOI":"10.2174\/0929867328666210810150940","volume":"29","author":"S Ministrini","year":"2022","unstructured":"Ministrini S, Carbone F. PCSK9 and inflammation: their role in autoimmune diseases, with a focus on rheumatoid arthritis and systemic lupus erythematosus. Curr Med Chem. 2022;29(6):970\u20139.","journal-title":"Curr Med Chem"},{"issue":"10","key":"3122_CR38","first-page":"e30330","volume":"14","author":"MA Ameer","year":"2022","unstructured":"Ameer MA, Chaudhry H, Mushtaq J, Khan OS, Babar M, Hashim T, et al. An overview of systemic lupus erythematosus (SLE) pathogenesis, classification, and management. Cureus. 2022;14(10):e30330.","journal-title":"Cureus"},{"issue":"6","key":"3122_CR39","first-page":"541","volume":"34","author":"C Fang","year":"2018","unstructured":"Fang C, Luo T, Chen X, Lin L. Elevated level of serum PCSK9 in patients with systemic lupus erythematosus. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2018;34(6):541\u20135.","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"issue":"1","key":"3122_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/metabo13010027","volume":"13","author":"Y Ding","year":"2022","unstructured":"Ding Y, Fan S, Tang Y, He M, Ren M, Shi Y, et al. The association between blood lipids and systemic lupus erythematosus: a two-sample Mendelian randomization research. Metabolites. 2022;13(1):27.","journal-title":"Metabolites"},{"key":"3122_CR41","doi-asserted-by":"publisher","first-page":"858653","DOI":"10.3389\/fgene.2022.858653","volume":"13","author":"M Wang","year":"2022","unstructured":"Wang M, Huang S, Lin X, Wen C, He Z, Huang L. The causal relationship between blood lipids and systemic lupus erythematosus risk: a bidirectional two-sample Mendelian randomization study. Front Genet. 2022;13:858653.","journal-title":"Front Genet"},{"key":"3122_CR42","doi-asserted-by":"publisher","first-page":"908831","DOI":"10.3389\/fimmu.2022.908831","volume":"13","author":"N Gao","year":"2022","unstructured":"Gao N, Kong M, Li X, Wei D, Zhu X, Hong Z, et al. Systemic lupus erythematosus and cardiovascular disease: a Mendelian randomization study. Front Immunol. 2022;13:908831.","journal-title":"Front Immunol"},{"issue":"1","key":"3122_CR43","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.autrev.2015.08.007","volume":"15","author":"M Frieri","year":"2016","unstructured":"Frieri M, Stampfl H. Systemic lupus erythematosus and atherosclerosis: review of the literature. Autoimmun Rev. 2016;15(1):16\u201321.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"3122_CR44","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00281-022-00922-y","volume":"44","author":"CB Oliveira","year":"2022","unstructured":"Oliveira CB, Kaplan MJ. Cardiovascular disease risk and pathogenesis in systemic lupus erythematosus. Semin Immunopathol. 2022;44(3):309\u201324.","journal-title":"Semin Immunopathol"},{"issue":"2","key":"3122_CR45","first-page":"e22027","volume":"14","author":"SB Jha","year":"2022","unstructured":"Jha SB, Rivera AP, Flores Monar GV, Islam H, Puttagunta SM, Islam R, et al. Systemic lupus erythematosus and cardiovascular disease. Cureus. 2022;14(2):e22027.","journal-title":"Cureus"},{"key":"3122_CR46","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jaut.2016.10.004","volume":"76","author":"GJ Pons-Estel","year":"2017","unstructured":"Pons-Estel GJ, Andreoli L, Scanzi F, Cervera R, Tincani A. The antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun. 2017;76:10\u201320.","journal-title":"J Autoimmun"},{"issue":"2","key":"3122_CR47","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1136\/annrheumdis-2018-213181","volume":"78","author":"E Frangou","year":"2019","unstructured":"Frangou E, Chrysanthopoulou A, Mitsios A, Kambas K, Arelaki S, Angelidou I, et al. REDD1\/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A). Ann Rheum Dis. 2019;78(2):238\u201348.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"3122_CR48","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1586\/erc.09.137","volume":"7","author":"PI Burgos","year":"2009","unstructured":"Burgos PI, Alarcon GS. Thrombosis in systemic lupus erythematosus: risk and protection. Expert Rev Cardiovasc Ther. 2009;7(12):1541\u20139.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"2","key":"3122_CR49","first-page":"221","volume":"21","author":"Y Pelegri","year":"2003","unstructured":"Pelegri Y, Cerrato G, Martinuzzo ME, Carreras LO, Forastiero RR. Link between anti-CD36 antibodies and thrombosis in the antiphospholipid syndrome. Clin Exp Rheumatol. 2003;21(2):221\u20134.","journal-title":"Clin Exp Rheumatol"},{"issue":"18","key":"3122_CR50","doi-asserted-by":"publisher","first-page":"4494","DOI":"10.1182\/bloodadvances.2020001609","volume":"4","author":"M Yang","year":"2020","unstructured":"Yang M, Li W, Harberg C, Chen W, Yue H, Ferreira RB, et al. Cysteine sulfenylation by CD36 signaling promotes arterial thrombosis in dyslipidemia. Blood Adv. 2020;4(18):4494\u2013507.","journal-title":"Blood Adv"},{"issue":"1","key":"3122_CR51","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1046\/j.1423-0410.1997.7310046.x","volume":"73","author":"P Borzini","year":"1997","unstructured":"Borzini P, Riva M, Nembri P, Rossi E, Pagliaro P, Vergani P, et al. CD36 autoantibodies and thrombotic diathesis, thrombocytopenia and repeated early fetal losses. Vox Sang. 1997;73(1):46\u20138.","journal-title":"Vox Sang"},{"issue":"7","key":"3122_CR52","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1136\/ard.2009.122374","volume":"69","author":"E Myasoedova","year":"2010","unstructured":"Myasoedova E, Crowson CS, Kremers HM, Fitz-Gibbon PD, Therneau TM, Gabriel SE. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis. 2010;69(7):1310\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"3122_CR53","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nrrheum.2014.121","volume":"10","author":"G Kerekes","year":"2014","unstructured":"Kerekes G, Nurmohamed MT, Gonzalez-Gay MA, Seres I, Paragh G, Kardos Z, et al. Rheumatoid arthritis and metabolic syndrome. Nat Rev Rheumatol. 2014;10(11):691\u20136.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"3122_CR54","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s11882-014-0497-6","volume":"15","author":"A Bag-Ozbek","year":"2015","unstructured":"Bag-Ozbek A, Giles JT. Inflammation, adiposity, and atherogenic dyslipidemia in rheumatoid arthritis: is there a paradoxical relationship? Curr Allergy Asthma Rep. 2015;15(2):497.","journal-title":"Curr Allergy Asthma Rep"},{"key":"3122_CR55","doi-asserted-by":"crossref","unstructured":"Meng Y, Zheng X, Zhang Z, Geng H, Li X. Circulating PCSK9 relates to aggravated disease activity, Th17\/Treg imbalance, and predicts treatment outcome of conventional synthetic DMARDs in rheumatoid arthritis patients. Ir J Med Sci. 2023.","DOI":"10.1007\/s11845-023-03323-8"},{"issue":"1","key":"3122_CR56","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13075-020-02386-7","volume":"23","author":"J Frostegard","year":"2021","unstructured":"Frostegard J, Ahmed S, Hafstrom I, Ajeganova S, Rahman M. Low levels of PCSK9 are associated with remission in patients with rheumatoid arthritis treated with anti-TNF-alpha: potential underlying mechanisms. Arthritis Res Ther. 2021;23(1):32.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"3122_CR57","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/apt.15562","volume":"51","author":"H Soh","year":"2020","unstructured":"Soh H, Im JP, Han K, Park S, Hong SW, Moon JM, et al. Crohn\u2019s disease and ulcerative colitis are associated with different lipid profile disorders: a nationwide population-based study. Aliment Pharmacol Ther. 2020;51(4):446\u201356.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7\u20138","key":"3122_CR58","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s00508-009-1150-6","volume":"121","author":"V Hrabovsky","year":"2009","unstructured":"Hrabovsky V, Zadak Z, Blaha V, Hyspler R, Karlik T, Martinek A, et al. Cholesterol metabolism in active Crohn\u2019s disease. Wien Klin Wochenschr. 2009;121(7\u20138):270\u20135.","journal-title":"Wien Klin Wochenschr"},{"issue":"1","key":"3122_CR59","doi-asserted-by":"publisher","first-page":"e002196","DOI":"10.1161\/CIRCGEN.118.002196","volume":"12","author":"CP Nelson","year":"2019","unstructured":"Nelson CP, Lai FY, Nath M, Ye S, Webb TR, Schunkert H, et al. Genetic assessment of potential long-term on-target side effects of PCSK9 (proprotein convertase subtilisin\/kexin type 9) inhibitors. Circ Genom Precis Med. 2019;12(1):e002196.","journal-title":"Circ Genom Precis Med"},{"issue":"1","key":"3122_CR60","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1038\/s41467-021-25703-3","volume":"12","author":"AF Schmidt","year":"2021","unstructured":"Schmidt AF, Hunt NB, Gordillo-Maranon M, Charoen P, Drenos F, Kivimaki M, et al. Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease. Nat Commun. 2021;12(1):5640.","journal-title":"Nat Commun"},{"issue":"9","key":"3122_CR61","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamacardio.2022.2333","volume":"7","author":"AJ Cupido","year":"2022","unstructured":"Cupido AJ, Reeskamp LF, Hingorani AD, Finan C, Asselbergs FW, Hovingh GK, et al. Joint genetic inhibition of PCSK9 and CETP and the association with coronary artery disease: a factorial Mendelian randomization study. JAMA Cardiol. 2022;7(9):955\u201364.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"3122_CR62","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.anai.2016.09.447","volume":"118","author":"J Peng","year":"2017","unstructured":"Peng J, Huang Y. Meta-analysis of the association between asthma and serum levels of high-density lipoprotein cholesterol and low-density lipoprotein cholesterol. Ann Allergy Asthma Immunol. 2017;118(1):61\u20135.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"3122_CR63","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12944-018-0807-4","volume":"17","author":"SH Ko","year":"2018","unstructured":"Ko SH, Jeong J, Baeg MK, Han KD, Kim HS, Yoon JS, et al. Lipid profiles in adolescents with and without asthma: Korea National Health and nutrition examination survey data. Lipids Health Dis. 2018;17(1):158.","journal-title":"Lipids Health Dis"},{"issue":"11","key":"3122_CR64","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1212\/01.WNL.0000145708.03876.C3","volume":"63","author":"MS Cartwright","year":"2004","unstructured":"Cartwright MS, Jeffery DR, Nuss GR, Donofrio PD. Statin-associated exacerbation of myasthenia gravis. Neurology. 2004;63(11):2188.","journal-title":"Neurology"},{"issue":"2","key":"3122_CR65","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jocn.2013.11.009","volume":"21","author":"J Gale","year":"2014","unstructured":"Gale J, Danesh-Meyer HV. Statins can induce myasthenia gravis. J Clin Neurosci. 2014;21(2):195\u20137.","journal-title":"J Clin Neurosci"},{"issue":"2","key":"3122_CR66","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378(2):169\u201380.","journal-title":"N Engl J Med"},{"issue":"2","key":"3122_CR67","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1034\/j.1600-0404.2002.01334.x","volume":"106","author":"F Giubilei","year":"2002","unstructured":"Giubilei F, Antonini G, Di Legge S, Sormani MP, Pantano P, Antonini R, et al. Blood cholesterol and MRI activity in first clinical episode suggestive of multiple sclerosis. Acta Neurol Scand. 2002;106(2):109\u201312.","journal-title":"Acta Neurol Scand"},{"issue":"14","key":"3122_CR68","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1177\/1352458516635873","volume":"22","author":"Y Wang","year":"2016","unstructured":"Wang Y, Bos SD, Harbo HF, Thompson WK, Schork AJ, Bettella F, et al. Genetic overlap between multiple sclerosis and several cardiovascular disease risk factors. Mult Scler. 2016;22(14):1783\u201393.","journal-title":"Mult Scler"},{"key":"3122_CR69","doi-asserted-by":"publisher","first-page":"292598","DOI":"10.1155\/2012\/292598","volume":"2012","author":"M Orth","year":"2012","unstructured":"Orth M, Bellosta S. Cholesterol: its regulation and role in central nervous system disorders. Cholesterol. 2012;2012:292598.","journal-title":"Cholesterol"},{"issue":"6","key":"3122_CR70","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1084\/jem.20021425","volume":"197","author":"O Aktas","year":"2003","unstructured":"Aktas O, Waiczies S, Smorodchenko A, Dorr J, Seeger B, Prozorovski T, et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med. 2003;197(6):725\u201333.","journal-title":"J Exp Med"},{"issue":"11","key":"3122_CR71","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1096\/fj.05-3861com","volume":"19","author":"AS Paintlia","year":"2005","unstructured":"Paintlia AS, Paintlia MK, Khan M, Vollmer T, Singh AK, Singh I. HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. FASEB J. 2005;19(11):1407\u201321.","journal-title":"FASEB J"},{"issue":"1","key":"3122_CR72","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12974-022-02409-x","volume":"19","author":"S Vigne","year":"2022","unstructured":"Vigne S, Duc D, Peter B, Rebeaud J, Yersin Y, Ruiz F, et al. Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis. J Neuroinflammation. 2022;19(1):42.","journal-title":"J Neuroinflammation"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03122-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-023-03122-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03122-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T14:34:12Z","timestamp":1700404452000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-023-03122-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,14]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3122"],"URL":"https:\/\/doi.org\/10.1186\/s13075-023-03122-7","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,14]]},"assertion":[{"value":"11 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The GWAS summary data used in this study were all from the online public platform (). The study protocols were approved by respective local ethics committees, and participants have provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"148"}}